We propose that NRG1 expression and EGFR activation signatures may enrich for improved efficacy of anti-ErbB3 therapeutic mAb approaches when combined with EGFR-targeting therapies in HNSCC. This evidence concerns the gene ERBB3 and head and neck squamous cell carcinoma.